Anavex Life Sciences Corp (AVXL)

[anders2211]

Leave open the possibility that the "methodology" from the
trial will be the focus? If that (pursuing the science)
becomes the spin it would be disappointing.

I was about to ask the same question.

11.00 a.m LB25 - ANAVEX®2-73 (blarcamesine) Currently in Phase 2b/3 Early Alzheimer’s Disease (AD): Analysis of Cognitive Outcome
Measures Relevant in AD of Double-blind, Multicenter, Placebo-controlled Phase 2 Clinical Trial in 132 Patients with Parkinson’s
Disease Dementia
Dag Aarsland (1), Jaime Kulisevsky Bojarski (2), Mohammad Afshar (3), Coralie Williams (3), Frederic Parmentier (3), Martin
Kindermans (3), Tayo Fadiran (4), Andy Mattai (4), Christopher U Missling (4), Walter E Kaufmann (4)
(1)King’s College - London (United Kingdom); (2)University of Barcelona - Barcelona (Spain); (3)Ariana Pharma - Paris (France); (4)Anavex Life
Sciences - New York, NY (United States)

where does it say Missling is going more into detail on the PDD data?